Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 15,045	$ 11,813
Short-term bank deposits	14,846	14,858
Notes receivable	2,138	4,373
Accounts receivables, net	20,150	19,589
Inventories, net	7,878	6,337
Prepaid assets and other current assets	8,161	2,625
Total current assets	68,448	64,786
Property and equipment, net	23,518	23,880
Intangible assets, net	5,083	273
Deferred tax assets	5,818	5,619
Long-term certificates of deposit	21,367	24,568
Other assets, noncurrent	5,556	6,280
Total assets	129,790	125,406
Current liabilities:
Accounts payable	122	108
Contract liabilities	28	61
Due to related parties	228	227
Accrued expenses and other current liabilities	17,239	10,615
Income tax payable	569	2,831
Operating lease liabilities, current	805	713
CVR derivative liability	0	4,961
Total current liabilities	18,991	19,516
Operating lease liabilities, noncurrent	780	885
Deferred government grants	905	928
Warrant liability, noncurrent	3,413	5,668
Other noncurrent liabilities	1,399	7
Total liabilities	25,488	27,004
Commitments and Contingencies (Note 12)
Stockholders' equity:
Common stock, $0.001 par value, 400,000,000 shares authorized; 87,636,209 shares and 86,307,544 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	87	86
Additional paid-in capital	138,179	136,185
Statutory reserve	3,098	3,098
Accumulated deficit	(70,755)	(73,453)
Accumulated other comprehensive loss	(2,486)	(2,597)
Total Gyre stockholders' equity	68,123	63,319
Noncontrolling interest	36,179	35,083
Total equity	104,302	98,402
Total liabilities and stockholders' equity	129,790	125,406
GC Biopharma Corp
Current assets:
Receivable from GCBP	0	4,961
GNI
Current assets:
Other receivables from GNI	$ 230	$ 230